The 100,000 Genomes Project is up and running in the United Kingdom. And with the population-scale sequencing drive having already made breakthroughs in identifying rare diseases, Genomics England has handed out $12 million to bolster its data analysis capabilities.
RainDance Technologies has taken a step toward completing its long-planned IPO by filing the paperwork for a $60 million offering.
Foundation Medicine has followed up its transformational deal with Roche by inking an oncology alliance with Eisai-backed H3 Biomedicine. The deal sees Foundation Medicine pair its genomic database with H3's computational biology capabilities.
The Financial Times has taken a look inside Chinese sequencing giant BGI and the implications of its mission to sequence the genomes of one million humans, one million microorganisms and one million plants and animals.
Personalis has returned to the financing font ahead of a planned scaling up of its operations. The Menlo Park, CA-based genome sequencing and interpretation company has reported interest from pharma companies in its cancer services, a trend that helped persuade investors to give it $33 million in a Series C round.
Having given a $60 million boost to 23andMe last week, Genentech has now turned to J. Craig Venter's Human Longevity for help sequencing and analyzing tens of thousands of genomes.
Days after unveiling a $60 million deal with Genentech, personal genomics pioneer 23andMe struck a new database-driven collaboration with Pfizer. There is even talk of a possible resolution with the FDA in 2015.
NextCODE has made a sharp exit. Just 15 months after some ex-deCode Genetics executives struck a deal with Amgen to create NextCODE, Chinese CRO WuXi PharmaTech has bought the genomic analysis startup for $65 million in cash.
Genentech has given 23andMe a major boost. The big biotech has reportedly paid $10 million upfront and agreed to $50 million in milestones to access 23andMe's database for target discovery of new drugs for Parkinson's disease.
Having started 2014 with major doubts hanging over its genomics operations, Roche closed the year with a renewed focus on the sector. The latest step in its plan was completed just before the holidays, when Roche agreed to buy Bina Technologies for its next-generation sequencing data analysis platform.